在美股交易时段，医疗设备公司NeuroPace Inc.（股票代码：NPCE）股价出现显著上涨，盘中大涨6.41%。截至最新报价，该股报16.58美元/股，成交量达1.6896万股，换手率为0.05%，振幅达6.96%。
股价上涨的主要原因是摩根大通（JP Morgan）上调了NeuroPace的评级和目标价。根据最新报告，摩根大通维持对NeuroPace的"增持"评级，并将目标价从14.00美元上调至16.00美元。这一积极的评级调整显然提振了投资者信心，推动了股价的上涨。
值得注意的是，NeuroPace是一家专注于癫痫治疗的商业化阶段医疗设备公司。公司的主要产品RNS系统旨在通过减少或消除癫痫发作来改善患者的生活质量。在整体医疗器械行业中，NeuroPace所在的细分领域当日整体上涨0.51%。此外，根据最新财报数据，NeuroPace实现营业收入22.52百万美元，但净利润为-6.59百万美元，每股收益为-0.21美元。尽管公司目前仍处于亏损状态，但摩根大通的评级上调表明分析师对公司的未来发展持积极态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.